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Background: Common variable immunodeficiency (CVID) is the most common primary 
immunodeficiency. Prevalence varies greatly between countries and studies. Most diag-
nostic criteria include hypogammaglobulinemia and impaired vaccine response.
aim: To evaluate the minimum prevalence as well as the clinical and immunological 
phenotypes of CVID in Southern Finland.
Methods: We performed a cross-sectional study to assess all adult CVID patients 
followed up in three hospital districts in Southern and South-Eastern Finland between 
April 2007 and August 2015. CVID diagnosis was based, with a minor modification, on 
the ESID/PAGID criteria for primary CVID. Antipolysaccharide responses to Pneumovax® 
were defined as impaired only if 50% or more of the serotypes did not reach a level of 
0.35 µg/mL after vaccination. We further characterized the patients’ B cell phenotypes 
and complications associated with CVID.
results: In total, 9 patients were excluded due to potential secondary causes before 
diagnosis. ESID/PAGID criteria were met by 132 patients (males 52%), of whom, 106 had 
“probable” and 26 “possible CVID.” Based on the population statistics in the three hospi-
tal districts, the minimum adult prevalence per 100,000 inhabitants in Finland for all CVID 
(“probable CVID,” respectively) patients was 6.9 (5.5). In the highest prevalence district 
(Helsinki and Uusimaa), the prevalence was 7.7 (6.1). CVID patients suffer from frequent 
complications. Ten patients died during follow-up. Of probable CVID patients, 73% had 
more than one clinical phenotype. Intriguingly, gradual B cell loss from peripheral blood 
during follow-up was seen in as many as 16% of “probable CVID” patients. Patients with 
possible CVID displayed somewhat milder clinical and laboratory phenotypes than prob-
able CVID patients. We also confirm that large granular lymphocyte lymphoproliferation 
is a CVID-associated complication.
TaBle 1 | Prevalence of CVID in various countries.
country Prevalence of 
cViD/100,000
% of cViD of total 
number of primary 
immunodeficiencies
reference
Denmarka 3.8 n.a. (8)
Iceland 3.1 17 (7)
Norway 2.6 31 (3)
Turkey 1.4 5 (4)
United Kingdom 1.3 37 (5)
Switzerland 1.2 45 (6)
France 0.7 14 (1)
Spain 0.6 21 (2)
CVID, common variable immunodeficiency; n.a., not available.
aIn two Danish regions, the prevalence was 5/100,000.
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conclusion: The prevalence of CVID in Finland appears the highest recorded, likely 
reflecting the genetic isolation and potential founder effects in the Finnish population. 
Studies to discover potential gene variants responsible for the high prevalence in Finland 
thus seem warranted. Increased awareness of CVID among physicians would likely lead 
to earlier diagnosis and improved quality of care.
Keywords: primary immunodeficiency, common variable immunodeficiency, prevalence, primary antibody 
deficiency, secondary antibody deficiency, hypogammaglobulinemia
patients (throughout the article, “probable” and “possible CVID” 
refer to ESID/PAGID criteria). Clinical phenotypes were defined 
by clinical complications associated with CVID (17).
MaTerials anD MeThODs
study Population
Patients were initially diagnosed with CVID in 1960–2015. 
CVID diagnosis was re-assessed in all follow-up patients with 
IgG substitution therapy. Historical patients without vaccine 
response data (n = 56) were considered to have CVID if at least 
two of the three main immunoglobulin classes (IgG, IgA, IgM) 
had been below reference without apparent secondary causes 
noted at diagnosis or during early follow-up. Between February 
2007 and August 2015, patients with low levels of at least two of 
the three main immunoglobulin classes IgG, IgA, and IgM were 
immunologically assessed using previously published routine 
accredited laboratory methods (18).
Pneumococcal vaccine responses were assessed at the Finnish 
National Institute for Health and Welfare, as previously described 
(13, 15). Of patients with vaccine response data, the majority were 
tested for responses to seven serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) 
(13) and the rest to 10 serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 
23F) (15). Patients were defined to have poor responses to polysac-
charide antibodies if at least 50% of the measured serotype-specific 
antipneumococcal polysaccharide antibody titers were below 
0.35 µg/mL 4 weeks after vaccination with Pneumovax® (15).
Participating outpatient clinics were the only ones providing 
adult ambulatory care for primary immunodeficiencies in these 
areas, exclusively authorized to assess reimbursement criteria for 
long-term IgG replacement therapy. All patients living within the 
Hospital District of Helsinki and Uusimaa and followed up at the 
Adult Immunodeficiency Unit of Helsinki University Hospital 
(HUH), as well as individuals in the respective districts and out-
patient clinics in Kymenlaakso Social and Health Services (Carea) 
and South Karelia Social and Health Care District (Eksote) were 
systematically assessed for CVID using the above-listed inclusion 
criteria. Patients with CVID who visited HUH for consultation 
only from outside the study area were excluded from analyses. 
No data were available for patients younger than 16 years of age 
at the end of the study.
cViD criteria Used
We used the ESID/PAGID criteria to define CVID, with the 
 exception that patients with impaired vaccine responses, normal 
IgG, and below reference concentration of plasma IgM and IgA 
inTrODUcTiOn
Common variable immunodeficiencies (CVID) are jointly the 
most common clinically significant primary immunodeficiencies 
in the world. The prevalence varies greatly between countries, 
ranging from 3.8/100,000 in Denmark to 0.6/100,000 in Spain 
(Table 1) (1–8). There are also geographical differences in setting 
diagnosis. CVID has classically been diagnosed using the old 
ESID/PAGID criteria (9). In recent years, new criteria, such as the 
revised ESID Registry (10), Ameratunga (11), and International 
Consensus Document (ICON) (12) criteria suggest updated 
approaches to diagnosing CVID. The largest differences between 
countries in setting a diagnosis within these criteria lie in the 
interpretation of antipolysaccharide vaccine responses. Current 
practices and guidelines differ greatly between countries, with 
major variation in definitions due to small or unpublished control 
populations (13–15). The most stringent serotype-specific criteria 
suggested are based on population-derived data and advocate a 
threshold of 0.35 µg/mL for protectivity (15).
There are no contemporary studies available on the prevalence 
of CVID in Finland (16). The aim of this study was to estimate 
the minimum adult (aged ≥16 years) prevalence of CVID in three 
hospital districts in Finland that jointly serve approximately 1.9 
million inhabitants (i.e., ≈38% of the Finnish population). To 
delineate a universally accepted minimum prevalence of CVID 
in Finland, the cut-offs of impaired antipneumococcal polysac-
charide responses to a non-conjugated 21-valent pneumococcal 
vaccine (Pneumovax®) were based on the stringent population-
based data from population-based vaccine response studies 
(15). We studied the patients’ B cell and clinical phenotypes and 
compared the findings between “probable” and “possible CVID” 
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were moved into the “possible CVID” category (9). We also 
required the clinical phenotype during follow-up to be typical for 
CVID. If in the historical cohort, a secondary cause was suspected 
or the patient tolerated IgG therapy poorly, patients were reevalu-
ated with pneumococcal antibody response testing after a pause 
in IgG replacement therapy with a 4- to 6-month washout period. 
If they refused reassessment, they were excluded from the cohort. 
Pretreatment IgG levels for the historical cohort were 0.0–3.8 
(median 1.4) g/L and below 3.8 for all. If a combined immuno-
deficiency was suspected clinically during follow-up, we excluded 
those with at least two of the following: low CD4 counts, low naïve 
CD4 cell counts, and/or absent T cell proliferation. Due to the long 
follow-up available, these were not systematically assessed without 
prior clinical suspicion in patients diagnosed >4 years before the 
end of study. Those fulfilling late-onset combined immunode-
ficiency (LOCID) criteria based on having a CD4+ T-cell count 
lower than 200 × 106 cells/L on more than one occasion, without 
explainable cause, were retained in the cohort (19).
clinical Phenotyping
We assessed five clinical phenotypes (17). To enable comparisons 
between previously published cohorts, “autoimmunity” included the 
following inflammatory conditions: idiopathic thrombocytopenia 
purpura (ITP), autoimmune hemolytic anemia (AIHA), hyper- and 
hypothyroidism, diabetes mellitus type 1, vitiligo, psoriasis, alope-
cia, rheumatic arthritis, celiac disease, pernicious anemia, atrophic 
gastritis, autoimmune neutropenia, sialadenitis, and primary 
sclerosing cholangitis. “Polyclonal lymphoproliferation” included 
lymphoid interstitial pneumonia, lymphadenopathy, splenomegaly, 
granulomatous-lymphocytic interstitial lung disease (GLILD, 
proven with biopsy or typical radiology) and other, biopsy-proven 
granuloma (excluding Crohn’s disease). The other three phenotypes 
were “malignancies,” “non-infectious gastrointestinal disease,” and 
“infections only” (17). Due to the high variability of gastrointestinal 
complications in CVID patients, these were all listed under one 
subheading and will be described separately.
immunophenotyping
Lymphocyte and B cell phenotyping were performed as previ-
ously published (20). Briefly, for flow cytometry, cells in EDTA 
samples were stained using whole blood technique, and ana-
lyzed on a FACSCanto II flow cytometer [Beckton Dickinson 
(BD) Biosciences, San Jose, CA, USA]. To establish the relative 
and absolute numbers in each lymphocyte subset (CD3+ T cells, 
CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD16+CD56+ 
NK  cells), MultiTEST CD3 (clone SK7), FITC/CD8 (clone 
SK1), PE/CD45 (clone Hle-1), PerCP/CD4 (clone SK3), APC, 
and CD3 FITC/CD16 (clone B73.1) +  CD56 (clone NCAM 
16.2), PE/CD45 PerCP/CD19 (clone SJ25C1), APC reagents, 
and TruCOUNT Tubes (BD Biosciences) were used accord-
ing to manufacturer’s instructions. To establish the relative 
numbers in B memory cell subsets, 100 µl of whole blood was 
washed three times with phosphate-buffered saline, followed 
by staining for 15 min at room temperature with the following 
antibodies at optimal concentrations: anti-IgD FITC (clone 
IA6-2), anti-IgM APC (clone G20-127), CD19 PE-Cy7 (clone 
SJ25C1), CD21 PE (clone B-ly4), CD27 PE (clone L128), CD38 
PerCP-Cy5.5 (clone HIT2), and CD45 APC-Cy7 (clone 2D1) 
all from BD Biosciences. After lysis of red blood cells with the 
BD FACS Lysing Solution (BD Biosciences) and washing, data 
acquisition was performed on a FACSCanto II flow cytometer. 
A minimum of 5,000 CD19+ lymphocytes was acquired. Data 
were further analyzed using FACS Diva software version 6.1.3 
(BD Biosciences), and B cell subsets determined according to 
Wehr et al. (20).
Data handling and analyses
Coded data were collected into an online database created 
using Microsoft Access. The database held categories containing 
demographic information, laboratory results used in different 
classification criteria, clinical phenotypes, and infections. Those 
without data were excluded from sub-analyses.
The database had mandatory fields to ensure the quality of the 
study as well as pre-filled alternatives to choose from to minimize 
errors. Cytopenias were defined as neutropenia, lymphopenia, or 
thrombocytopenia below 2.5 centile for more than 3  months. 
Chronic or recurrent gastroenteritis was defined as ≥3 bacterial 
or viral gastroenteritis and/or chronic excretion of virus to feces 
over 3 months.
The robustness of CVID diagnosis was compared between the 
original ESID/PAGID (1999), the Ameratunga (2013), and the 
ICON (2015) criteria (9, 11, 12). No comparisons to the revised 
ESID registry criteria (2014) were performed due to its debatable 
exclusion of CVID-like patients with low levels of IgG and IgM 
but normal IgA and for the lack of systematic naïve CD4 cell and 
lymphocyte proliferation data in historical patients (12, 21).
Prevalence calculations were based on the reported popula-
tion figures given by Statistics Finland (http://www.stat.fi/til/
vrm_en.html) and on the known hospital district populations. 
Using the Access database, relationships between clinical 
manifestations and differences between patients in the hospital 
districts were analyzed.
Microsoft Excel and IBM SPSS Statistics 22.0 were used for the 
analysis. Frequencies and co-expression of CVID clinical compli-
cations were studied using descriptive the statistics/frequencies 
and crosstabs functions. For comparisons of continuous variables 
between groups, the Mann–Whitney U-test was used. p-Values 
<0.05 were considered significant.
ethics
The study was approved by the Coordinating Ethics 
Committee of the Helsinki and Uusimaa Hospital District 
(138/13/03/00/2013).
resUlTs
Demographics
Of 141 patients, nine were considered to have secondary CVID 
(non-Hodgkin lymphoma 7, unclassified hematologic disease 2; 
4 had received treatment with rituximab), and were not studied 
further. Of the remaining 132 patients with primary CVID, 106 
patients were diagnosed with “probable CVID” and 26 patients 
with “possible CVID” according to the ESID/PAGID criteria. Of 
FigUre 1 | Age at diagnosis (a) and age at the time of the study (B). 106 patients with “probable CVID.”
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the 26 patients with “possible CVID,” 25 had low levels of IgG, 
with impaired antipneumococcal polysaccharide responses (spe-
cific antibody deficiency) and normal IgA and IgM levels. One 
previously published “possible CVID” patient with an NFKB1 
I553M mutation had normal IgG but low IgA and IgM levels as 
well as impaired antipneumococcal vaccine responses and would 
have been classified as “probable CVID” in the original ESID/
PAGID criteria (22). Of the remaining 106, four patients were 
diagnosed with LOCID. The age of patients at diagnosis and at 
the time of the study is presented in Figures 1A,B. Of the 106 
FigUre 2 | Infections (%) in probable and possible CVID patients. No 
statistical differences were noted between “probable” and “possible CVID” 
patients. GU, genitourinary. Sepsis includes patients with a severe bacteremic 
infection leading to hospitalization.
TaBle 3 | Numbers of patients with CVID according to three diagnostic criteria.
esiD/PagiD ameratunga icOn
Probable CVID 106 109 –
Possible CVID 26 23 –
Definite CVID 0 0 63 (113a)
ESID, European Society for Immunodeficiencies; PAGID, Pan-American Group for 
Primary Immunodeficiencies; ICON, International Consensus Document.
aWhen historical patients, who otherwise fulfill ICON criteria, but lack vaccine response 
data, have been added into the total count.
TaBle 2 | Estimated minimum adult prevalence of “probable” and combined 
“probable” and “possible CVID” in the studied Finnish hospital districts according 
to 1999 ESID/PAGID criteria.
hospital District 
of helsinki and 
Uusimaa (hUs)
hospital District 
of Kymenlaakso 
(carea)
hospital 
District of 
south carelia 
(eksote)
Finland
Population (n) 1,616,300 171,000 131,155 5,500,000
Probable CVID 6.1 2.9 1.5 5.5
Possible CVID 1.6 0 0 1.4
CVID, common variable immunodeficiency.
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“probable CVID” patients, the male/female sex ratio was 1.1; 
ratios in different age groups (in years) were as follows: <30:4; 
30–59:1.1; >59:0.78. The age range in years for the whole CVID 
cohort was 9–74 at diagnosis and 20–84 at the time of study. Of 
the nine CVID patients diagnosed before age 20, eight (89%) 
were male. Of the 29 CVID patients diagnosed before age 30, 20 
(68%) were male. Ten patients died during the study, three due 
to gastrointestinal carcinomas, while there were single cases of 
myeloid sarcoma, subarachnoid hemorrhage, acute myocardial 
infarction, suspected substance intoxication; three remained 
unknown. The mean age of death was 61.3 years.
Prevalence of cViD in Finland
We studied how prevalent patients in the studied hospital dis-
tricts with “probable CVID” and “possible CVID” were according 
to ESID/PAGID criteria (Table 2). Based on available data, the 
minimum adult prevalence of CVID in Finland was 6.9/10,000 
(5.5/10,000 for “probable CVID”), reaching 7.7/10,000 (6.1/10,000 
for “probable CVID”) in the university teaching hospital district 
(HUS).
comparisons between Different cViD 
criteria
We compared ESID/PAGID, Ameratunga, and ICON criteria for 
setting the CVID diagnosis (Table 3) (9, 11, 12). When using the 
ESID/PAGID criteria, our study consisted of 106 “probable” and 
26 “possible” CVID patients. The Ameratunga criteria yielded 
109 probable and 23 possible CVID patients. ICON criteria only 
diagnose definite CVID, and our study had 63 such patients. 
However, if all the historical patients lacking vaccine response 
tests who otherwise fulfill the ICON criteria were included, the 
number of definite CVID patients in the whole study area would 
have been 113 (prevalence 5.9/100,000).
clinical Manifestations
A history of infections was noted in 104 (98%) “probable CVID” 
patients. The most frequent significant infections were pneumo-
nia, sinusitis, sepsis, genitourinary infections, and skin abscesses 
(Figure  2). Associated clinical manifestations are shown in 
Figure  3. Within the cohort of “probable CVID” patients, 54 
(51%) patients suffered from at least one autoimmune disorder. 
The most common autoimmune manifestations were ITP and 
AIHA (Figure 3). Altogether, 61 (58%) patients had polyclonal 
lymphocytic proliferation, of which lymphadenopathy and sple-
nomegaly were the most frequent. Gastrointestinal disease was 
seen in 21 (20%) patients and 11 (10%) patients had granulomas. 
Other frequently occurring conditions were asthma (24%) and 
bronchiectasis (43%) (Figure  3). Malignancy was reported 
in 14% of “probable CVID” patients; these 16 malignancies 
in 15 patients included five non-Hodgkin lymphomas, three 
gastrointestinal cancers, three breast cancers, one large granular 
lymphocyte (LGL) leukemia, as well as single cases of myeloid 
sarcoma, melanoma, cervical, and renal carcinoma (Figure 4). 
Interestingly, altogether, four “probable CVID” patients had 
some form of LGL lymphoproliferation (LGL-L). Out of the 
defined clinical phenotypes, 21 (20%) “probable CVID” patients 
had only one, while the rest had up to all five phenotypes 
(Figure 5). Among the 26 “possible CVID” patients, five malig-
nancies, each with a single case, were found: non-Hodgkin and 
Hodgkin lymphoma, cervix cancer, chronic myeloid leukemia, 
and lung cancer.
clinical Differences between Probable and 
Possible cViD Patients
The overall number of infections (Figure 2), recurrent HSV (5 vs 
15%, p = 0.074), bronchiectasis (43 vs 27%, p = 0.180), asthma 
(24 vs 39%, p = 0.141), autoimmunity (51 vs 35%, p = 0.36), and 
malignancy (14 vs 19%, p =  0.55) were not different between 
“probable” and “possible CVID” patients, respectively. However, 
FigUre 5 | Different phenotypes (%) in probable and possible CVID. Phenotypes 
are abbreviated as follows; also their combinations are used: I, infections; M, 
malignancies; A, autoimmunity; P, polyclonal lymphocytic proliferation; G, 
gastrointestinal disease. Asterisks mark statistical significance between “probable” 
and “possible CVID” patients, *p < 0.05 (Fisher’s 2-sided Exact test).
FigUre 4 | Malignancies (%) in probable CVID patients. Other four cancers 
include one cervical cancer and one renal carcinoma, one melanoma, and 
one myeloid sarcoma. LGL, large granular lymphocytic.
FigUre 3 | Complications (%) in probable and possible CVID patients. Asterisks mark statistical significance between “probable” and “possible CVID” patients, 
*p < 0.05 (Fisher’s 2-sided Exact test or Pearson Chi-square, as appropriate). For each complication, data are presented with pairwise bars for “probable” and 
“possible CVID” where “probable CVID” is first and with darker color. Sicca diagnosis was based on doctor-assessed symptoms and findings.
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polyclonal lymphocytic proliferation (70 vs 35%, respectively, 
p = 0.001), especially splenomegaly (39 vs 12%, p = 0.016) and 
lymphadenopathy (37 vs 15%, p = 0.039), were more frequent in 
“probable CVID” (Figure 3). While infections were more com-
mon in “probable CVID” (98 vs 85%, p = 0.014), these patients 
also had more additional comorbidities. Therefore, there were 
more patients with infections only among “possible CVID” (36 
vs 15%, p = 0.019) (Figure 5). All in all, patients with “probable 
CVID” could be divided into 16 clinical phenotypic combinations 
and “possible CVID” into 12 clinical phenotypic combinations. 
The dominant phenotypes covering altogether 67.9% of “probable 
CVID” patients were “infections only” and infections in com-
bination with “autoimmunity” and/or “polyclonal lymphocytic 
proliferation” (Figure 5).
TaBle 4 | Mean immunoglobulin plasma concentration and the lymphocyte subclasses in possible and probable CVID.
group igg igM iga ige cD19+ cD3+ cD4+ cD8+
Reference range 6.8–15 0.47–2.84 0.08–1.4 0–110 0.08–0.62 0.75–2.76 0.404–1.612 0.22–1.13
Unit g/L g/L g/L IU/L ×109/L ×109/L ×109/L ×109/L
Possible CVID Mean 5.81 0.76 0.89 35.50 0.21 1.46 0.87 0.58
SD 2.36 0.47 0.70 86.73 0.12 0.62 0.44 0.29
n 26 26 26 26 26 26 26 26
Probable CVID Mean 2.30** 0.32** 0.17** 4.56** 0.15* 1.35 0.63* 0.69
SD 1.64 0.61 0.20 8.01 0.17 1.15 0.37 0.86
n 106 106 106 99 103 103 104 103
Ig, immunoglobulin, given for each as a mean of plasma concentrations (gram per liters). Flowcytometry of lymphocytes was used to quantitate subclasses (number of cells ×109/L). 
CD3: T-lymphocytes; CD19: B-lymphocytes, CD4: T-lymphocytes helper, CD8: T-lymphocytes suppressor. n, number of patients. Asterisks mark statistical significance between 
possible and probable CVID patients, *p < 0.01 and **p < 0.001 (Mann–Whitney U-test).
FigUre 6 | B-cell phenotyping results (%) in probable and possible CVID patients. Abbreviations: B−, CD19+ B cells ≤1% of lymphocytes; smB−, switched 
memory B cells ≤2% of B cells; 21low, CD21low cells ≥10% of B cells; Tr-high, transitional B cells ≥9% of B cells (in total, 129 CVID patients had B-cell 
phenotyping data available. Transitional B cells had been studied in 114 subjects). Asterisks mark statistical significance between “probable” and “possible CVID” 
patients, *p < 0.01 (χ2-test).
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laboratory Differences between Probable 
and Possible cViD Patients
Chronic thrombocytopenia was more frequent in “probable” 
than “possible CVID” (33 vs 4%, p = 0.001), while chronic neu-
tropenia was found similarly in both (16 vs 12%, p = 0.76). Of 
note, there was a trend, albeit statistically insignificant, toward 
more frequent chronic lymphopenia in “probable CVID” (44 vs 
27%, p = 0.126). The numbers of CD19+ B and CD4+ T cells and 
the concentrations of immunoglobulin A, G, M, and E were lower 
in “probable” than in “possible CVID” patients (Table 4).
In B  cell phenotyping according to EUROclass, differences 
between “probable” and “possible CVID” were observed (20). 
The percentage of patients with CD19+ B  cells <1% of all 
lymphocytes was 16% in “probable CVID” and 4% in “possible 
CVID” (p =  0.192). In patients with CD19+ B  cells >1% of all 
lymphocytes, CD27, CD21, and IgM expression were analyzed. 
Class-switched memory B cells (CD27+IgM−) were <2% of CD19+ 
B lymphocytes in 62% of patients with “probable CVID” and in 
12% of patients with “possible CVID” (p < 0.001). In “probable 
CVID,” 50% of patients had >10% of activated (CD38lowCD21low) 
B cells vs 20% of patients in “possible CVID” (p = 0.007). Finally, 
only 4% of patients with “possible CVID” had, according to 
EUROclass, both low percentages of class-switched B cells and 
high percentages of activated B  cells, while this was found in 
36% of patients with “probable CVID” (p =  0.001) (Figure 6). 
Also, patients with GLILD had significantly lower class-switched 
memory B cells compared to those without GLILD (p < 0.001). 
Interestingly, when comparing B cell phenotypes and the risk of 
malignancy among all 132 CVID patients, 35.3% of patients with 
B cell loss, defined as <1% total lymphocytes being CD19+ B cells, 
had malignancies vs 12.2% of those without B cell loss (p = 0.024). 
CD16+ CD56+ NK  cell counts did not differ between patients 
with or without malignancy. Low class-switched memory B cells 
were associated with autoimmunity (p = 0.025) and polyclonal 
lymphocytic proliferation (p < 0.001). Increased percentages of 
8Selenius et al. CVID in Finnish Adults
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activated B  cells according to EUROclass were associated with 
polyclonal lymphocytic proliferation (p < 0.001).
Patients with low igg and low igM but 
normal iga
Unlike recently published diagnostic criteria, the ESID 2014 
registry inclusion criteria suggest that patients with normal IgA 
but with low IgG and IgM should not be called CVID. We found 
three such patients in our “probable CVID” cohort. In two of 
them, the phenotype was “infections only.” One, however, had 
a typical, severe CVID phenotype with malignancy, autoim-
munity, and infections. All three patients had class-switched 
memory B cells above 2% of B cells and normal CD21 expres-
sion. The lowest IgG in these patients averaged 4.2 g/L (3.9–4.5) 
vs average of 2.3 ± 1.6 g/L (±SD) in the “probable CVID” group 
as a whole.
DiscUssiOn
Common variable immunodeficiency is the most common 
primary immunodeficiency in the world, with published preva-
lences ranging from 0.4 to 3.8/100,000 (Table 1) and an estimated 
prevalence ranging from 2/100,000 to 4/100,000 (21). However, 
our study showed a minimum adult prevalence of 6.9/100,000 
(5.5/100,000 for “probable CVID”) in Finland (Table 2), the high-
est population prevalence ever reported. After a previous report’s 
prevalence of 2/100,000, this higher Finnish prevalence is likely 
due to improved diagnosis and awareness (16). Of the other Nordic 
countries, Denmark has the previously highest recorded preva-
lence of 3.8/100,000, while Iceland has 3.1/100,000 and Norway 
2.1/100,000. In Central and Southern Europe, the prevalences 
vary from 1.3/100,000 in the United Kingdom to 0.6/100,000 in 
Spain (Table 1). We chose to exclude all patients with secondary 
causes to CVID. However, the diagnosis of primary vs secondary 
antibody deficiency can be very difficult in individual patients. 
Furthermore, patients with primary immunodeficiencies fre-
quently receive immunosuppressive medication and display a 
combination of PID and secondary immunodeficiency.
The prevalence of CVID in the studied hospital districts 
varied from 1.5/100,000 in the easternmost Southern Finland to 
7.7/100,000 in the greater Helsinki area (p =  0.006). However, 
due to the relatively small sizes of studied hospital districts out-
side greater Helsinki, even a single new patient would strongly 
influence the prevalence in those areas (Table  2). Prevalence 
differences may furthermore reflect lack of awareness for pri-
mary immunodeficiencies among local doctors and a need for 
improved screening and referral practices. Genetically, the popu-
lation around Helsinki capital area originates from continuous 
migration over centuries from all regions of country and likely 
represents the entire Finnish population well. Thus, its adult 
prevalence of CVID of 7.7/100,000 (6.1 for “probable CVID”) 
further suggests a need for countrywide improvements in referral 
practices.
The observed differences between the three diagnostic criteria 
stemmed mainly from varying demands for diagnostic findings. 
Since ICON requires vaccine responses, it was the most restric-
tive in our partly historical cohort, while in vaccine response-
studied patients, other assessed criteria seemed strictest. As 
there was disagreement for probable/definite CVID between 
different criteria in only eight patients (8%), most patients with 
typical CVID seemed unproblematic to diagnose. In practice, a 
much wider variation in setting a diagnosis of CVID between 
patient cohorts likely stems from different criteria used to define 
impaired vaccine responses (15, 23, 24). The poor specificity of 
previously promoted seroresponse criteria has recently been 
proven formally in the to date largest cohort of Belgian control 
subjects (23). Since only a subset of our patients’ antipneumococ-
cal responses was studied with a similar bead-based multiplex 
assay as in the Belgian study, direct comparisons were rendered 
difficult. However, both suggested sets of reference cut-offs result 
in clearly smaller numbers of CVID patients than if the AAAAI 
criteria for vaccine responses were used (15, 23, 24).
Common variable immunodeficiency was equally common in 
men as in women. However, males presented at an earlier age than 
females, corroborating earlier studies (21). In older patients, the 
prevalence was higher among females. Whether this represents 
earlier onset in males or delayed diagnosis in females remains to 
be studied.
Comparing the phenotypes of Finnish CVID patients to those 
in other published cohorts, the phenotypes of CVID patients in 
Britain seem closest (25). Even though Western Finns and Swedes 
share a common genetic background, the phenotypes reported 
in Swedish CVID patients appear clearly different (25, 26). Most 
of our patients had multiple non-infectious complications. Even 
though most patients had a history of infections, only 23% had 
a clinical picture with infections only. Furthermore, 73% of our 
patients displayed more than one phenotype. All in all, our patients 
could be categorized into 18 different combined phenotypes (17). 
This was in stark contrast to a previous European study where 
83% of the patients had only one phenotype (25).
Interestingly, though LGL-L has occasionally been described 
as a complication of CVID, it occurred during follow-up as fre-
quently as in four of 132 patients (3%) in our cohort (27). One of 
the patients with LGL-L further developed LGL leukemia. LGL-L 
is a well-known phenomenon in, for example, GATA2 and STAT3 
gain-of-function mutated patients, who may also mimick CVID 
phenotype (28, 29). Our CVID patients with LGL-L underwent 
whole exome sequencing and exclusion of GATA2 haploinsuf-
ficiency at the RNA level, without findings. Thus, our results 
confirm that LGL-L is a true CVID-associated complication and 
emphasize that primary immunodeficiency should be excluded 
in patients with LGL-L.
In general, “possible CVID” patients had fewer clinical phe-
notypes than those with “probable CVID” (Figure 5). “Possible 
CVID” patients presented with a single phenotype in 54% while 
this was seen only in 20% of “probable CVID” patients (p < 0.001, 
Fisher’s 2-sided exact test). This was especially true concerning 
infections and polyclonal lymphocytic proliferation. Also, B cell 
phenotypes were less frequently abnormal among “possible” 
than “probable CVID” patients. As reported previously by others 
(20), low class-switched memory B  cells were associated with 
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autoimmunity and lymphoproliferation. In “B  cell loss,” B  cell 
numbers were low at diagnosis and frequently lead to the disap-
pearance of B cells in blood during follow-up. Interestingly, in our 
cohort, B cell loss seemed to be associated with malignancy, but 
numbers are small. Both B cell loss and propensity to malignan-
cies could hypothetically reflect some uncharacterized genetic 
predisposition and requires further study. To the best of our 
knowledge, B  cell loss also seems somewhat more common in 
Finland than in previously reported cohorts.
With the exception of the one previously published patient 
with low IgA, IgM, and an NFKB1 I553M mutation (22), “possible 
CVID” patients displayed “IgG deficiency” (low IgG together 
with impaired antipneumococcal polysaccharide responses). Our 
“possible CVID” or “IgG deficiency” cohort was thus largely iden-
tical to a suggested group of patients with “idiopathic primary 
hypogammaglobulinemia,” and our findings largely corroborate 
earlier reports (22).
Our findings in three clinically typical “probable CVID” 
patients suggested that patients with normal plasma IgA levels, 
low IgG, low IgM, and impaired polysaccharide responses 
should, despite their rarity, also be called CVID. This became 
one of the reasons not to compare the ESID 2014 registry cri-
teria to other criteria. However, we also agree with the notion 
that those with for example prolonged lymphocyte subclass 
cytopenias and low naïve CD3+CD4+ T  cells or mitogen 
responses would most likely need a separate diagnostic class. 
Such patients may represent hitherto uncharacterized com-
bined immunodeficiencies.
A major weakness in our study was its retrospective nature. 
Also, the lack of systematic assessment for T  cell deficiency in 
our historical cohort should be regarded as a further weakness, 
only partly offset by the long follow-up periods in such patients. 
Further, due to the lack of systematically collected registry data, 
we could not assess the prevalence of CVID in patients ≤16 years 
of age at the end of the study; the true prevalence of CVID in 
Finland is thus likely even higher than the 7.7/100,000 found in 
the greater Helsinki area. However, all pediatric CVID patients 
in the study area are systematically referred to the study units at 
age ≥16; our available results thus suggest that pediatric-onset 
of CVID seems surprisingly rare in Finns (Figure  1). We are 
currently entering both pediatric and adult primary immunode-
ficiency patients into a dedicated registry within our electronic 
patient record system.
Whole exome sequencing has been carried out on 51 patients 
in our cohort (data not shown). In them, only three unpublished 
patients with known disease-associated TNFRSF13B risk muta-
tions and two published patients with a disease-causing NFKB1 
I553M mutation were found (22). Our prevalence results thus 
suggest an autosomal recessive condition and a founder effect of 
yet unknown gene(s) (26, 30). The high prevalence of CVID in 
Finland may be explained partly by Scandinavian genetic influ-
ence and partly, like in pathogenic AICDA M139T mutations, by 
the so-called Finnish Disease Heritage. This is characterized by 
enrichment of rare mutation(s) in a genetically isolated popula-
tion (26, 30–32). The genetic background in Finland generally cor-
relates with geography. The Eastern population is a well-defined 
founder population, with later migration to Northern Finland (26, 
30–32). Whether the high prevalence of CVID in the Helsinki area 
stems from the Eastern, Western, or both subpopulations, remains 
to be studied. If the observed high prevalence indeed genetically 
also stems from the Eastern genetic isolate, increased awareness in 
primary care and remittal for assessment will be especially needed 
in Northern and Eastern Finland.
To conclude, we report an unprecedentedly high (adult) 
prevalence of CVID from Finland. Our results suggest unknown 
disease causing gene(s) in the Finnish CVID population, a known 
genetic isolate (26, 30–32). In the future, Finland may become an 
optimal country to study the etiology of CVID due to suspected 
founder effects, a limited amount of background genetic variation, 
access to hospital and registry data covering the whole country, 
an advanced biobank law and robust research infrastructure. Our 
goal will be to search for gene candidates in the known familiar 
and geographic clusters of CVID in Finland. Recognizing patients 
with CVID earlier improves patient outcomes and the quality and 
cost efficiency of care (33). Thus, raised awareness about CVID 
especially among primary and secondary care physicians in 
Finland will be needed to facilitate diagnosis in areas of Finland 
with low reported prevalence.
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